Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.
Added: Nov 03, 2011 3:04 pmThe Defense Medical Materiel Program Office (DMMPO) Medical Materiel Enterprise Standardization Office (MMESO) announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of Surgical Masks. The MMESO Europe is the lead MMESO for this project.
The primary objective of this effort is to standardize the quality of care across the Military Treatment Facilities (MTFs) and operational assemblages based on the critical balance of clinical efficacy and value. The intent for this initiative is the standardization of a clinically preferred product(s) and source for institutional and operational medicine requirements at the best price for each MMESO Area of Responsibility (AOR). It is also intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). Standardized products must be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance expectations as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical acceptability, then clinically preferred, best value will determine selection for each MMESO AOR. It is intended that the selected standardized vendor(s) for this Standardization Action (SA) support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. Vendor is not required to quote for each MMESO AOR. The Government will make a single selection for each of the following MMESO AORs:
1. MMESO North
2. MMESO South
3. MMESO West
4. MMESO Pacific
5. MMESO Europe
The major facilities in the MMESOs include, but are not limited to MMESO North: Walter Reed National Military Medical Center, Naval Medical Center Portsmouth, Wright-Patterson Medical Center; MMESO South: Wilford Hall Medical Center, Brooke Army Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital; MMESO West: Naval Medical Center San Diego, Madigan Army Medical Center, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific: Tripler Army Medical Center, Honolulu, HI, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe: Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, the 48th Medical Group, Lakenheath, UK; and Operational U.S. Forces.
This IA standardization initiative will be a Three Phase IPP Process: vendor (s) who meets the technical / company requirements in Phase I will be invited to advance and participate Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be run concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is December 2011. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost will determine selection for each MMESO AOR. Points of Contact: Mr. Robert Halliday, Clinical Analyst, Robert.email@example.com and COM 011-49-6221-172108 or Mr. Tom Winkel, Team Leader, Tom.firstname.lastname@example.org and COM 011-49-6221-172106.
B. Products & Performance Required.
C. Instructions to Vendors
D. Source Selection Procedures
Technical/Company Requirements: During the acquisition planning procedures the MMESO CPT validated/approved the company/technical requirements outlined below. The ten (10) requirements below must be answered and all supporting documentation provided with the vendor's initial submittal by the response date stated in the FBO announcement. A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I.
Clinical Performance Requirements
The clinical/performance acceptability evaluation period will last for fourteen (14) calendar days. The acceptability evaluation responses will be in a Likert scale format with a one (1) through five (5) scoring range. The scale descriptors are: one (1)-Completely Unacceptable, two (2)-Overwhelmingly Unacceptable, three (3)-Partially Unacceptable, four (4)-Acceptable, and five (5)-Highly Acceptable. The MMESO JPRB has established a 4.0 as the Clinically Preferred threshold of products for standardization. A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative.
A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. Of those vendors who are qualified as clinically preferred, selection will be based on best price. A vendor who has been disqualified or has not been selected will be notified in writing upon completion of the standardization selection. Clinical /performance acceptability evaluations by the participating CPT facilities will be tabulated resulting in one score per participating MMESO per vendor. The participating MMESOs' scores by vendor will then be combined resulting in one final vendor performance evaluation score. All clinical/performance acceptability evaluations will be tabulated by the MMESO Europe and results will be forwarded to the MMESO CPT for final review.
There will be approximately fourteen (14) MTFs enterprise wide that will be evaluating products.
Clinical/Performance Requirements: During the acquisition planning procedures the MMESO CPT validated/approved the clinical/performance requirements outlined below:
Please consult the list of document viewers if you cannot open a file.
Technical / Company Requirement Response Document
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Technical / Company Requirement Response Document
November 3, 2011
Description: Use this document for all your responses. Fill in the attachment and provide with your initial submittal to this FBO RFIAQ. *A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I. *Vendor who does not meet the deadline of COB on the date/time listed in the FBO, will be disqualified from further consideration in the standardization initiative. *Please remember to attach your product literature and catalogs required in the Federal Business Opportunity.
700 Robbins Avenue
Philadelphia, Pennsylvania 19111-5096
Dept G4, Bldg 3613, Rm 0055
Heidelberg, Nachrichten Kaserne, APOAE09042
November 3, 2011
Nov 28, 2011 5:00 pm Eastern
Automatic, 15 days after response date
December 13, 2011
Original Set Aside:
65 -- Medical, dental & veterinary equipment & supplies
339 -- Miscellaneous Manufacturing/339113 -- Surgical Appliance and Supplies Manufacturing